RT Journal Article
SR Electronic
T1 A systematic review and meta-analysis of inpatient mortality associated with nosocomial and community COVID-19 exposes the vulnerability of immunosuppressed adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.10.21260306
DO 10.1101/2021.07.10.21260306
A1 Ponsford, Mark J.
A1 Ward, Tom JC
A1 Stoneham, Simon
A1 Dallimore, Clare M.
A1 Sham, Davina
A1 Osman, Khalid
A1 Barry, Simon
A1 Jolles, Stephen
A1 Humphreys, Ian R.
A1 Farewell, Daniel
YR 2021
UL http://medrxiv.org/content/early/2021/07/14/2021.07.10.21260306.abstract
AB Background Little is known about the mortality of hospital-acquired (nosocomial) COVID-19 infection globally. We investigated the risk of mortality and critical care admission in hospitalised adults with nosocomial COVID-19, relative to adults requiring hospitalisation due to community-acquired infection.Methods We systematically reviewed the peer-reviewed and pre-print literature from 1/1/2020 to 9/2/2021 without language restriction for studies reporting outcomes of nosocomial and community-acquired COVID-19. We performed a random effects meta-analysis (MA) to estimate the 1) relative risk of death and 2) critical care admission, stratifying studies by patient cohort characteristics and nosocomial case definition.Results 21 studies were included in the primary MA, describing 8,246 admissions across 8 countries during the first wave, comprising 1517 probable or definite nosocomial COVID-19, and 6729 community-acquired cases. Across all studies, the risk of mortality was 1.31 times greater in patients with nosocomial infection, compared to community-acquired (95% CI: 1.01 to 1.70). Rates of critical care admission were similar between groups (Relative Risk, RR=0.74, 95% CI: 0.50 to 1.08). Immunosuppressed patients diagnosed with nosocomial COVID-19 were twice as likely to die in hospital as those admitted with community-acquired infection (RR=2.14, 95% CI: 1.76 to 2.61).Conclusions Adults who acquire SARS-CoV-2 whilst already hospitalised are at greater risk of mortality compared to patients admitted following community-acquired infection; this finding is largely driven by a substantially increased risk of death in individuals with malignancy or who had undergone transplantation. These findings inform public health and infection control policy, and argue for individualised clinical interventions to combat the threat of nosocomial COVID-19, particularly for immunosuppressed groups.Systematic review registration: PROSPERO CRD42021249023Competing Interest StatementThe authors have declared no competing interest.Clinical TrialSystematic review registration: PROSPERO CRD42021249023Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=249023 Funding StatementThis work was partly funded by UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC). MJP is supported by the Welsh Clinical Academic Training (WCAT) programme and a Career Development Award from the Association of Clinical Pathologists, and is a participant in the NIH Graduate Partnership Program. IH is a Wellcome Trust Senior Research Fellow in Basic Biomedical Sciences. The funding sources did not have any role in designing the study, performing analysis or communicating findings.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data from previous published studies in which relevant consent and ethical approvals were obtained by primary investigators were retrieved and analysed, therefore no ethical approval was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analysed for this study will be made available upon written request to the corresponding author.